PT Kalbe Farma Tbk : Company Update FY 2024 Audited Results (16 April 2025)

About this update from Pt Kalbe Farma Tbk

Company Update FY24 PT Kalbe Farma Tbk April 2025 Table of Content • Key Updates 04 • Business Strategies 08 • Financial Overview 23 • Appendix 1 30 • Appendix 2 37 Key Updates More than Half a Century of Providing Wide-Range Healthcare Solutions Market Capitalization IDR 63.8 tn ($3.9 bn) * free float 42.01% * Corporate Overview Indonesian integrated healthcare company with regional footprint 1966 1991 Onwards Established, headquartered Listed in the The most integrated healthcare company in in Jakarta Indonesia Stock Exchange Southeast Asia Including treasury stocks * As of 31 Dec 24 Prescription Pharmaceuticals 33.4% 28.3% Consumer Health Net Sales IDR 32,628 bn FY 2024 Nutritionals (Audited) 13.2% 25.1% Distribution & Logistics 6% Export ± 40 Countries Middle East SEA South Africa Solid Foundation for Future Growth Key Takeaways Strategic Partnerships and Investments 7.2% FY24 Audited 17.3% FY24 Audited Net Sales growth EPS growth Strengthening product portfolio through collaboration Strategic Partnership with Alliance Pharma Co.,Ltd. (Thailand) Key Updates Positive organic top-line growth driven by volume Progressing on track in key projects to drive future growth Recovery of gross margin trend Driving marketing effectiveness to sustain growth Key Risks Global financial and geopolitical volatility impact to currency and supply chain Pace of purchasing power recovery in domestic market Zerpidio and Efesa commercialization Established JV Livzon Pharma Indonesia to manufacture pharmaceuticals ingredients Radiopharmaceuticals facilities (cyclotron) Local Content Requirement in medical devices for Dialyzer, Mobile X-Ray, CT- Scan, endoscopy, USG machine Driving Growth and Improving Healthcare Resilience through Innovation 2025 Key Strategies Investing for long term growth through innovation and collaboration Prescription Medical International Pharmaceuticals Devices Market Consumer Health & Nutritionals Distribution & Logistics Innovative Biologics products, including expanding Insulin business and cell therapy Strengthen our position in the market Build local manufacturing capability Strengthen network and collaboration Bring more products to export markets Focus on selected countries Expand into preventive and wellness category Strengthen nutritional presence in affordable and ready-to-drink categories New potential principals Strengthen medical and distribution channel Strengthen portfolio in Vaccine Accelerate technology transfer Comply with local content requirements Optimize Alliance Pharma to bring biologics product to Thai market Business Strategies Driving Top Line Growth with Portfolio Strategy Prescription Pharmaceuticals Building Participation in Enhance Business Specialty Portfolio National Health Growth Steadily growing specialty Insurance by leveraging on category with Consistent growth strong commercial expanding innovative team and distribution in E-Catalog portfolio, supported by network local manufacturing Strategic Collaborations to Accelerate Growth Prescription Pharmaceuticals Sustaining Business Expansion through Strategic Partnerships Livzon Pharma Indonesia Shareholder Agreement Signing Jul 2024 To locally manufacture more advanced pharmaceuticals ingredients for the export market, by looking at the potential for use in the domestic market in the future Exclusive Collaboration signing May 2024 To increase market penetration and the availability of Kalbe products in the SEA, particularly Thailand JV establishment Dec 2022 To secure raw materials, open potential future expansion in China, and reduce dependence on the use of the US dollar Completion Dec 2022 To strengthen portfolio in focused therapeutic classes (Diabetic and Cardiovascular) and access to new category such as vaccines Oncology Biological-based Other Complete product range in all segments covering licensed, branded and unbranded generics Attention : This is an excerpt of the original content. To continue reading it, access the original document here .

View stock analysis, news, and events for Pt Kalbe Farma Tbk